RTP Mobile Logo

ASCOHem15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2015 and 56,630 individuals will die from these diseases.

LeukemiaTT115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

GITumorPanel

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastric and pancreatic cancer.

OVERVIEW OF ACTIVITY
Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 8% of all cancer deaths. Although individually less frequently encountered, the collection of noncolorectal gastrointestinal (GI) cancers account for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined.

COCMM15/2

OVERVIEW OF ACTIVITY

LCUTT115

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

COCP15/5

OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

ONSOvarian2015

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

OVERVIEW OF ACTIVITY

ONSCRC2015

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal cancer (CRC).

OVERVIEW OF ACTIVITY

ONSLung2015

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).

OVERVIEW OF ACTIVITY

BiomarkersTT115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast and colon cancer.

ONUMM115

OVERVIEW OF ACTIVITY

GynOnc15

TARGET AUDIENCE
This activity is intended for gynecologic and medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

OVERVIEW OF ACTIVITY

RTPODNHNT2015

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of head and neck cancers and thyroid cancer.

Hematologic Oncology Update, Issue 1, 2015

OVERVIEW OF ACTIVITY

COCP15/4

OVERVIEW OF ACTIVITY
In 2015 in the United States alone, it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.